We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Wi-Fi Securities Limited is a cyber security company that aims to revolutionise the security of public access Wi-Fi. To realise this vision, the company is developing a unique patent-protected system called SpriteGuard™ which will protect you and your data from hackers by stopping you connecting to fake hotspots. The system is targeted towards the $550 bn worldwide hospitality industry and has the ability to expand to other large global markets like city-wide free Wi-Fi, airports and coffee shops. Moreover, Wi-Fi Securities Limited has a highly experienced Wi-Fi Securities management board that has a track record of delivering multi-million-pound projects from concept to successful commercial deployment.

Pitch Rated

77%

Overall

rating powered by

CROWD RATING™

days to go: Extended investment: £1,014,708
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Morgan Goodwin is a UK-based company that pioneers the Combined Trading Platform (CTP) category, offering a comprehensive online platform for small businesses engaged in physical goods trading, along with specialized software development services, and a broad-spectrum business consultancy approach aimed at enhancing growth, efficiency, and technological advancement.
days to go: Stretch investment: £788,519
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Doqit offers a solution for managing life admin tasks, helping you organize important information, set action dates, and receive timely reminders, ultimately streamlining tasks like insurance renewals and warranties to reduce unnecessary expenses and simplify your life. It provides secure storage and easy access for vital information, transitioning from chaos to simplicity.  Security is also a priority for Doqit. The platform ensures that your sensitive information is stored securely, giving you peace of mind knowing that you can access your important documents and data whenever you need them, all within a few clicks.
days to go: Extended investment: £87,500
UTU is a company dedicated to building the trust infrastructure for the evolving web 3.0. They aim to facilitate safer and more reliable interactions between users and platforms by utilizing a decentralized reputation and reviews protocol. This protocol involves a non-tradable reputation token (UTT) that users can stake to endorse others, leading to positive outcomes. UTU's focus initially lies in Web3 and DeFi apps, where they provide AI-powered tools to curate trust signals and help users engage confidently in various online activities. They offer a range of products, including the UTU Trust Token, Browser Extension, and Trust API/SDK, all aimed at enhancing trust and security in digital interactions.
days to go: Extended investment: £150,000
Medic Bleep is a simple, secure and innovative patient-focused solution to communication challenges that healthcare professionals and the wider team in the UK National Health Service (NHS) face while going about their everyday work. It is saving each nurse & each junior doctor an estimated 48 minutes per shift. This coincides with the UK's Department of Health calling for a ban on pagers. If implemented across the NHS, it could free up the time to care for an estimated 11,000 nurses. To ensure data privacy and safety, the company allows communication to occur via the app. As a result of these safeguards and its user-friendly portal, the company's app has been downloaded 16,000 times by UK doctors and nurses. With the funds raised, the company will aim to solve looming technology gaps for over 30% of the NHS in the next 3 years and expand globally.

Pitch Rated

83%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £814,600
FutureBricks is an asset-backed lending platform for SME housebuilders and retail investors. It is a peer-to-peer (P2P) lending platform for SME housebuilders who have limited access to mainstream finance. In 2018, the company launched an online platform and mobile application with full-fledged automated lending. It has raised more than £2.8 million from just retail lenders across 16 projects. FutureBricks also maintained a 100% track record and 0% default rate of expected returns to investors to date. FutureBricks is named one of the most promising high-growth tech firms in the UK, by SVC2UK. FutureBricks was also shortlisted as “One to Watch” by London Business Awards 2019. With the investment received, the company will scale its marketing efforts and expand its commercial team to uplift and expand revenue-generating streams.
days to go: Expired investment: £474,120
Muniy makes banking easy for everyone, spreading a digital banking revolution with a focus on improving user experience, not only for familiar banking functions, but extending into other areas, such as retail experience, where people spend money. With Muniy's recently launched personal mobile money application as well as Muniy contactless card in the UK and Europe, the company aims to be at the forefront of banking innovation. The application can be used to pay via QR code, Mastercard, or for P2P transactions. By paying with Muniy, customers connect with merchants anonymously allowing the latter to profit from lower transaction processing costs. The company aims to introduce personalised rewards to its customers and soon launch the application in the Middle East. The company will utilise the investments to run a pilot in the UK and the European Union is a political and economic union of 27 member, and leverage a mature market to establish a foundation quickly in order to introduce their core financial services to key markets in the Middle East.

Pitch Rated

43%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £207,510
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph